Saol Therapeutics Completes BEACON Trial Enrollment for Knee Pain Treatment
News related to:Saol Therapeutics · 1 min read
ROSWELL, Ga., DUBLIN and HAMILTON, Bermuda, Oct. 8, 2026 /CourierPR/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, has announced the completion of patient enrollment in its pivotal Phase III BEACON trial, evaluating the safety and efficacy of SL1002 for the treatment of chronic pain related to osteoarthritis of the knee. The trial, which began in 2025, enrolled over 20 U.S. sites and was completed on October 2, 2026. Topline results are expected in the second quarter of 2027.
The BEACON trial is a Phase III, randomized, double-blind, placebo-controlled, multicenter study. It is designed to evaluate the safety and efficacy of SL1002, an investigational, novel, targeted perineural chemoneurolytic injection utilizing Saol's proprietary CYCLOPHLEX™ technology. The trial is being conducted in patients with chronic pain due to osteoarthritis of the knee, a condition that affects millions of people in the United States, according to the NCHS Data Brief, no 518, published by the National Center for Health Statistics in Hyattsville, MD.
Saol Therapeutics has also secured an End-of-Phase II meeting with the FDA to discuss the clinical development program for SL1002 in the treatment of spasticity. This program will explore the potential of SL1002 in treating spasticity, an additional indication for the product. The company plans to initiate an additional Phase III study in its knee pain program to support a planned regulatory filing, while also advancing multiple studies evaluating SL1002 in additional indications for the treatment of chronic pain and spasticity.
The completion of enrollment in the BEACON trial is a critical milestone for Saol Therapeutics. The company's commitment to developing innovative therapies for chronic pain and spasticity is evident in its ongoing clinical trials and regulatory discussions. The results of the BEACON trial and the upcoming FDA meeting will be crucial in determining the future of SL1002 as a non-opioid treatment option for millions of patients suffering from chronic pain and spasticity.